Unfortunately, those who have coverage through state or federal programs (e.g
In terms of weight loss effectiveness , semaglutide GLP-1 does have an edge over liraglutide, according to current research
They are also not recommended in individuals with certain conditions such as inflammatory bowel disease, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia
Another limitation is the lack of behavioral assessments beyond escape latency, which could provide a more comprehensive evaluation of cognitive function
Consult the pharmaceutical packaging of each GLP-1 medication for a complete list of drug interactions, safety information, side effects, warnings and additional information